Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the successful completion of a multi-year study investigating the application of cold atmospheric plasma (CAP) in the lung. The study, which focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine, confirms the potential of cold plasma as a non-pharmacological treatment option for severe infectious lung diseases.
The data reveal a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models. A key component was ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School, using an isolated, ventilation- and perfusion-capable lung model that mimics key physiological characteristics of the human lung.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated, "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems. It is particularly encouraging that we are already seeing first successful applications in patients."
Based on the study results, Viromed's technology has already been used in a university setting for a severe pulmonary case in a human patient following ethics committee approval. A university hospital with a lung and transplantation medicine department treated a patient with massive complications after a lung transplant, and the use of cold plasma was very successful. The treating physicians described the positive clinical course as exceptional, and further severely ill patients with high risk of fatal outcomes are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology, especially as classical pharmacological therapies face increasing resistance. The physical mode of action of cold plasma opens a new therapeutic dimension, including prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in bacterial endocarditis surgeries or thoracic application for bacterial pleural empyema.
For more information, visit Viromed Medical AG and view the original release on NewMediaWire.
